Lv4
700 积分 2023-07-19 加入
Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant
2天前
求助中
The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients
2天前
已完结
Analysis of CAR-Mediated Tonic Signaling
29天前
已完结
Population Pharmacokinetics of Tacrolimus in Adult Kidney Transplant Patients
1个月前
已完结
Total plasma protein effect on tacrolimus elimination in kidney transplant patients – Population pharmacokinetic approach
1个月前
已完结
Pharmacokinetics in Stable Kidney Transplant Recipients After Conversion From Twice-Daily to Once-daily Tacrolimus Formulations
1个月前
已完结
Unity brings strength: Combination of CAR-T cell therapy and HSCT
1个月前
已完结
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
1个月前
已完结
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
1个月前
已完结
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
2个月前
已关闭
皖公网安备34019202002308
